FDA Panel Recommends Savient Pharmaceuticals (SVNT) Gout Treatment
More News related to SVNT
- Savient Pharmaceuticals (SVNT) Reports Q3 Loss of $0.23
- Savient Pharmaceuticals Reports Third Quarter 2009 Financial Results
- Trading Radar for 11/04: Cisco (CSCO), Comcast (CMCSA), Tyco (TEL), Molson Coors (TAP) Report
- Savient Pharmaceuticals to Hold Third Quarter 2009 Financial Results Conference Call on Thursday, November 5, 2009
- Savient Pharmaceuticals to Present at the Oppenheimer 20th Annual Healthcare Conference
More News related to FDA
- Transcept Pharma (TSPT) to Meet with U.S. FDA To Discuss NDA Response Letter for Intermezzo
- DARA BioSciences (DARA) Says Clinical Trial on KRN5500 Achieved Its Primary Endpoint
- Nymox Pharmaceutical (NYMX) Announces Positive Clinical Data on BPH Drug NX-1207
- ARCA Biopharma (ABIO) Annouces Gencaro OK'd by U.S. FDA for Fast Track Program
- Ception and Cephalon (CEPH) Report Initial Results from Phase IIb/III Trial for CINQUIL(TM)
Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) announced that the Arthritis Advisory Committee appointed by the FDA recommended by a vote of 14 to 1 that KRYSTEXXA, a biologic PEGylated uricase enzyme, be granted marketing approval by the FDA for the treatment of refractory chronic gout.
Refractory chronic gout or treatment failure gout (TFG) is gout in patients who have failed to normalize serum uric acid and whose signs and symptoms are inadequately controlled with conventional urate-lowering therapy at the maximum medically appropriate dose or for whom conventional urate-lowering therapy is contraindicated. The current target Prescription Drug User Fee (PDUFA) action date for the FDA's decision as to whether to grant marketing approval for KRYSTEXXA is August 1, 2009.
Related Categories
FDAHot List
Stocks Mentioned
+0.00Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
